All News
ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis
An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).
Read Article
Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
Read Article
EULAR 2024 - Day 1 Report
Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
Read Article
Can we prevent psoriatic arthritis?
Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.
Read Article
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO.
Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis
A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.
Canary in a Coal Mine (4.19.2024)
Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.
Read Article
Window of Opportunity in Psoriatic Arthritis
A Dutch Early Psoriatic Arthritis cohort study shows that psoriatic arthritis (PsA) patients treated early (referred and diagnosed within in less than 12 weeks) had the best clinical outcomes.
2023 EULAR Psoriatic Arthritis Recommendations
EULAR has updated its treatment recommendations from the prior 2019 guidelines, since which there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.
Read Article
Expert Panel Guidance on Managing Psoriatic Arthritis and Comorbidities
An expert panel has published their consensus guidelines for the management of psoriatic arthritis (PsA) and it's comorbidities in the journal Rheumatology.
Read Article
Immunosuppression Increasing (2.23.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.
Read Article
Links:
Peter Nash drpnash ( View Tweet)
Peter Nash drpnash ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
